Abstract 1055P
Background
Efficient infiltration of activated T cells into tumors plays an important role in the therapeutic effect of adoptive cell immunotherapy. We previously modified T cells with a tumor-penetrating peptide iRGD (SmarT cells), and demonstrated that SmarT cells promote tumor-specific lymphocyte infiltration and enhanced the antitumor efficacy of PD-1 blocking strategy.
Methods
Here we report the interim analysis results of an ongoing phase 1/2 dose-escalation clinical trial of SmarT plus PD-1 mAb in patients with previously treated solid cancers (ChiCTR2200061306). The primary objective was safety for the combination of SmarT cells, low dose radiation and PD-1 mAb; secondary objectives included efficacy and dose-finding of SmarT cells. We treated 10 patients with three SmarT doses: 1.0 × 109, 5.0 × 109 or 1.0 × 109 cells. The low dose radiation (1Gy) was carried out 24 hours before SmarT injection.
Results
Three patients experienced a grade 2 fever. Two patients experienced a grade anemia. No cytokine release syndrome (CRS) occurred. No grade 3 or higher treatment-related adverse events or deaths were reported. A total of three patients had stable disease (SD) and seven patients had a progressive disease (PD). The disease control rate (DCR) reached 30.0%. The median progressive free survival time (mPFS) was 71 days and the median overall survival time (mOS) was 201 days.
Conclusions
These initial results suggest that SmarT cells has promising efficacy with an acceptable safety profile in patients with heavily pretreated, solid cancers.
Clinical trial identification
The trial protocol number is ChiCTR2200061306 and the release date 20 June 2022.
Editorial acknowledgement
Legal entity responsible for the study
The Ethics Committee of Nanjing Drum Tower Hospital.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1047P - AXA-042, a systemically administered TLR2/6 agonist, demonstrates target engagement and TLR pathway activation in patients with advanced solid tumors
Presenter: Ben Tran
Session: Poster session 19
1048P - Phase I/II Study of JK08, an IL-15 antibody fusion protein targeting CTLA-4, with unresectable locally advanced or metastatic cancer
Presenter: Nuria Kotecki
Session: Poster session 19
1049P - Phase Ib/II trial of envafolimab, a novel subcutaneous single-domain anti-PD-L1 monoclonal antibody, plus lenvatinib in patients with selected advanced solid tumors
Presenter: Tianshu Liu
Session: Poster session 19
1050P - Sensitization to immunotherapy through manipulation of tumor transcription by lurbinectedin
Presenter: Joan Russo-Cabrera
Session: Poster session 19
1051P - Intratumoral injection of LTX-315 in combination with pembrolizumab in patients with advanced melanoma refractory to prior PD-1/PD-L1 therapy: Interim results from the ATLAS-IT-05 trial
Presenter: Stephane Dalle
Session: Poster session 19
1052P - Phase-Ib trial of metformin combined with nivolumab for refractory/recurrent solid tumors
Presenter: Toshio Kubo
Session: Poster session 19
1053P - Tumor-restricted delivery of an immune-therapeutic payload by modified macrophages for the treatment of glioblastoma: The TEM-GBM STUDY (NCT03866109)
Presenter: Fabio Ciceri
Session: Poster session 19
1054P - A phase Ia study to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of a modular CLDN18.2-targeting PG CAR-T therapy (IBI345) in patients with CLDN18.2+ solid tumors
Presenter: Songbing Qin
Session: Poster session 19
1056P - Efficacy of spartalizumab across multiple cancer types in patients with PD1-high mRNA expressing tumors (SOLTI-1904 ACROPOLI)
Presenter: Aleix Prat
Session: Poster session 19
1057P - Long-term follow-up of a phase II study of tislelizumab (TIS) monotherapy in patients (pts) with previously treated, locally advanced, unresectable or metastatic microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) solid tumors
Presenter: Jian Li
Session: Poster session 19